Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-18. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
== Etymology == The earliest recorded use of the prefix step-, in the form steop-, is from an 8th-century glossary of Latin-Old English words meaning 'orphan'. Steopsunu is given for the Latin word filiaster and steopmoder for nouerca. Similar words recorded later in Old English include stepbairn, stepchild, and stepfather. The words are used to denote a connection resulting from the remarriage of a widowed parent and are related to the word ástíeped meaning 'bereaved', with stepbairn and stepchild occasionally used simply as synonyms for orphan. Words such as stepbrother, stepniece and stepparent appeared much later and have no particular connotation of bereavement. Corresponding words in other Germanic languages include Old High German stiuf- and Old Norse stjúp-.
The earliest reference to tomatoes being grown in British North America is from 1710, when herbalist William Salmon saw them in what is today South Carolina, perhaps introduced from the Caribbean. By the mid-18th century, they were cultivated on some Carolina plantations, and probably in other parts of the Southeast. Thomas Jefferson, who ate tomatoes in Paris, sent some seeds back to America. After 1860, it was often claimed that Americans believed that tomatoes were poisonous into the 1820s, but the belief was never widespread. When Alexander W. Livingston (1821–1898) began developing the tomato as a commercial crop, he had aimed to grow tomatoes smooth in contour, uniform in size, and sweet in flavor. He eventually developed over seventeen varieties. The U.S. Department of Agriculture's 1937 yearbook declared that "half of the major varieties were a result of the abilities of the Livingstons to evaluate and perpetuate superior material in the tomato". Livingston's first breed of tomato, the Paragon, was introduced in 1870. In 1875, he introduced the Acme, said to be in the parentage of most cultivars for the next twenty-five years. Other early breeders included Henry Tilden in Iowa and a Dr. Hand in Baltimore. Because of the tomato's need for heat and a long growing season, several states in the Sun Belt became major producers, particularly Florida and California. In California, tomatoes are grown under irrigation for both the fresh market and for canning and processing. The University of California, Davis's C.M.
== Cast == Aaron Kwok as Sean Lau (劉傑輝), Commissioner of Police Tony Leung Ka-fai as M.B. Lee (李文彬), retired Deputy Commissioner of Police (Operations) Chow Yun-fat as Oswald Kan (簡奧偉), Ex-judge, Court of First Instance of High Court / Senior Counsel / Current Legislator Charlie Young as Phoenix Leung (梁紫薇), Senior Assistant Commissioner of Police, Director of Management Services Janice Man as Isabel Au (歐詠恩), Barrister & mentee of Oswald Kan Eddie Peng as Joe Lee (李家俊), Ex-police constable / criminal & son of M.B. Lee Aarif Rahman as Billy Cheung (張國標), ICAC Principal Investigator Tony Yang as Roy Ho, Ex-Senior Police Constable Chang Kuo-chu as Peter Choi (蔡元祺), former Commissioner of Police (Cantonese dub: Kwok Fung) Wu Yue as Wu Tin-man, Ex-Senior Inspector of Police Ma Yili as Michelle Lau (陳雪兒), wife of Sean Lau Bibi Zhou as Alice Poon, Barrister Alex Tsui as Matthew Mak (麥啟文), ICAC Head of Operations Fan Zhibo as Rachel Ma, S.I.P. (VIP Protection Unit) Frankie Lam as Alan Au, current Deputy Commissioner of Police (Management) Kenny Wong as Stephen Han, current Deputy Commissioner of Police (Operations) / co-conspirator of Peter Choi Ram Chiang as David Mok, Senior Assistant Commissioner of Police, Director of Crime & Security, Phoenix Leung's mentor / co-conspirator of M.B.
Sources: en.wikipedia.org
Evidence of modern human habitation in Malaysia dates back 40,000 years. In the Malay Peninsula, the first inhabitants are thought to be Negritos. Areas of Malaysia participated in the Maritime Jade Road between 2000 BC to 1000 AD. Traders and settlers from India and China arrived as early as the first century AD, establishing trading ports and coastal towns in the second and third centuries. Their presence resulted in strong Indian and Chinese influences on the local cultures, and the people of the Malay Peninsula adopted the religions of Hinduism and Buddhism. Sanskrit inscriptions appear as early as the fourth or fifth century. The Kingdom of Langkasuka arose around the second century in the northern area of the Malay Peninsula, lasting until about the 15th century. Between the 7th and 13th centuries, much of the southern Malay Peninsula was part of the maritime Srivijayan empire. By the 13th and the 14th century, the Majapahit empire had successfully wrested control over most of the peninsula and the Malay Archipelago from Srivijaya. In the early 15th century, Parameswara, a runaway king of the former Kingdom of Singapura linked to the old Srivijayan court, founded the Malacca Sultanate. The spread of Islam increased following Parameswara's conversion to that religion. Malacca was an important commercial centre during this time, attracting trade from around the region.
=== Television === Phang has guest-directed on episodic series television, including for The Boys, Cloak & Dagger, Quantico, The Expanse, Riverdale, Major Crimes, The Exorcist, Proven Innocent, Stargirl and Resident Alien. She remarks that it is interesting to work in an established universe with characters already defined, and to direct a wide variety of actors who are already familiar with their characters. In her opinion, TV directing work, in addition to the extra income, improves her versatility and adaptability in her film projects.
=== Lebanon === On 6 November 2023, in response to the killing of four civilians in southern Lebanon, Prime Minister Najib Mikati announced that his government would submit an urgent complaint to the UN Security Council against Israel saying that its "targeting of civilians in its aggression against Lebanon" was a "heinous crime". Samir Geagea, the leader of a main Christian political party, blamed Hezbollah for attacking Israel and said that it harmed Lebanon while having no impact on Israel's Gaza offensive.
Albert Cardona is a neuroscientist and connectomics researcher who is a Programme Leader at the MRC Laboratory of Molecular Biology. and a Professor at the University of Cambridge in Cambridge, UK. He is also a Fellow at Pembroke College, Cambridge. His research maps neuronal circuits with synaptic resolution using volume electron microscopy, particularly in small animals such as the Drosophila, and studies how the structure of a neural circuit relates to its function
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.